There is provided a novel intermediate for producing pesticides. A method for producing the compound of Formula (3) comprises reacting an aromatic ketone compound of Formula (4) and a substituted acetophenone compound of Formula (5) as starting raw materials in an organic solvent or water in the presence or absence of an additive in the presence of a base in a suspended state. A method may comprise dehydrating the compound of Formula (3). A method for producing compound (2) in one step comprises reacting compound (4) and compound (5) to obtain compound (3). Further, a method for producing an isoxazoline compound of Formula (1) comprises reacting compound (2) and a hydroxylamine in an aliphatic or an aromatic hydrocarbon solvent which is optionally substituted by a halogen atom by adding an additive selected from a phase-transfer catalyst, a C.sub.1-C.sub.6 alcohol and an aprotic polar solvent in the presence of a base and water.

There is provided a novel intermediate for producing pesticides. A method for producing the compound of Formula (3) comprises reacting an aromatic ketone compound of Formula (4) and a substituted acetophenone compound of Formula (5) as starting raw materials in an organic solvent or water in the presence or absence of an additive in the presence of a base in a suspended state. A method may comprise dehydrating the compound of Formula (3). A method for producing compound (2) in one step comprises reacting compound (4) and compound (5) to obtain compound (3). Further, a method for producing an isoxazoline compound of Formula (1) comprises reacting compound (2) and a hydroxylamine in an aliphatic or an aromatic hydrocarbon solvent which is optionally substituted by a halogen atom by adding an additive selected from a phase-transfer catalyst, a C.sub.1-C.sub.6 alcohol and an aprotic polar solvent in the presence of a base and water.

Disclosed are a monomer represented by the following Chemical Formula 1 for a hardmask composition, a hardmask composition including the monomer, and a method of forming patterns using the same. ##STR00001##
In the above Chemical Formula 1, A, A, L, L, X and n are the same as defined in the specification.

Disclosed are a monomer represented by the following Chemical Formula 1 for a hardmask composition, a hardmask composition including the monomer, and a method of forming patterns using the same. ##STR00001##
In the above Chemical Formula 1, A, A, L, L, X and n are the same as defined in the specification.

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

Disclosed are a compound of Formula I,

##STR00001##

having higher inhibition of protein kinase G (PKG) activity and pharmaceutically acceptable salts thereof. In Formula I, R.sub.1 and R.sub.2 are the same or different, each being independently chosen from the halogens, the C.sub.1-C.sub.6 alkoxyl group, the C.sub.1-C.sub.6 alkyl group, the C.sub.2-C.sub.6 alkenyl group, and the C.sub.2-C.sub.6 alkynyl group; R.sub.3 is chosen from H, the halogens, the substituted or unsubstituted C.sub.1-C.sub.6 alkyl group, C.sub.3-C.sub.6 cycloalkyl group, C.sub.2-C.sub.6 alkenyl group, and C.sub.2-C.sub.6 alkynyl group, aryl group, and heteroaryl group; and n is an integer between 0 and 15. Also disclosed is a pharmaceutical composition comprising said compound, the use of the compound in treating pains, in particular chronic pain, a preparation method for the compound, and a new intermediate.

Disclosed are a compound of Formula I,

##STR00001##

having higher inhibition of protein kinase G (PKG) activity and pharmaceutically acceptable salts thereof. In Formula I, R.sub.1 and R.sub.2 are the same or different, each being independently chosen from the halogens, the C.sub.1-C.sub.6 alkoxyl group, the C.sub.1-C.sub.6 alkyl group, the C.sub.2-C.sub.6 alkenyl group, and the C.sub.2-C.sub.6 alkynyl group; R.sub.3 is chosen from H, the halogens, the substituted or unsubstituted C.sub.1-C.sub.6 alkyl group, C.sub.3-C.sub.6 cycloalkyl group, C.sub.2-C.sub.6 alkenyl group, and C.sub.2-C.sub.6 alkynyl group, aryl group, and heteroaryl group; and n is an integer between 0 and 15. Also disclosed is a pharmaceutical composition comprising said compound, the use of the compound in treating pains, in particular chronic pain, a preparation method for the compound, and a new intermediate.

Disclosed are a compound of Formula I, ##STR00001##
having higher inhibition of protein kinase G (PKG) activity and pharmaceutically acceptable salts thereof. In Formula I, R.sub.1 and R.sub.2 are the same or different, each being independently chosen from the halogens, the C.sub.1-C.sub.6 alkoxyl group, the C.sub.1-C.sub.6 alkyl group, the C.sub.2-C.sub.6 alkenyl group, and the C.sub.2-C.sub.6 alkynyl group; R.sub.3 is chosen from H, the halogens, the substituted or unsubstituted C.sub.1-C.sub.6 alkyl group, C.sub.3-C.sub.6 cycloalkyl group, C.sub.2-C.sub.6 alkenyl group, and C.sub.2-C.sub.6 alkynyl group, aryl group, and heteroaryl group; and n is an integer between 0 and 15. Also disclosed is a pharmaceutical composition comprising said compound, the use of the compound in treating pains, in particular chronic pain, a preparation method for the compound, and a new intermediate.

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.